1. Signaling Pathways
  2. GPCR/G Protein
  3. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19755
    S-5751
    Antagonist
    S-5751 is an orally active prostaglandin DP receptor antagonist. S-5751 inhibits cAMP generation in platelet-rich plasma induced by PGD2 with IC50 0.12 μM. S-5751 has anti-inflammatory activity. S-5751 can be used in asthma research.
    S-5751
  • HY-108564
    L 655240
    Antagonist
    L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders.
    L 655240
  • HY-182513
    ONO-8539
    Antagonist
    ONO-8539 is an orally active prostanoid EP1 receptor antagonist with competitive, insurmountable binding and slow receptor dissociation for long-duration inhibition. ONO-8539 modulates afferent nerve function related to bladder activity, inhibits detrusor overactivity-related contractions, decreases nonvoiding contractions and voiding duration, and increases uroflow rate with ATP (HY-B2176)-induced detrusor overactivity. ONO-8539 attenuates acid-induced heartburn symptoms, extends time to first heartburn sensation, and prevents primary hypersensitivity after distal esophageal acidification. ONO-8539 can be used for the research of overactive bladder and gastroesophageal reflux disease.
    ONO-8539
  • HY-131664
    EP3 antagonist 2
    Antagonist
    EP3 antagonist 2 (Compound Exp 1) is a potent and selective EP3 receptor antagonist. EP3 antagonist 2 has a strong binding affinity for the human EP3 receptor (Ki: 3.3 nM) and significant antagonistic activity (IC50: 30.8 nM, determined by cellular cAMP levels).
    EP3 antagonist 2
  • HY-108563AR
    SC 51089 free base (Standard)
    Antagonist
    SC 51089 free base (Standard) is the analytical standard of SC 51089 (free base) (HY-108563A). This product is intended for research and analytical applications. SC 51089 free base is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity.
    SC 51089 free base (Standard)
  • HY-102065R
    SC-19220 (Standard)
    Antagonist
    SC-19220 (Standard) is the analytical standard of SC-19220 (HY-102065). This product is intended for research and analytical applications. SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption.
    SC-19220 (Standard)
  • HY-121720
    L 657925
    Antagonist
    L 657925 is a potent thromboxane A2 (TXA2) antagonist. L 657925 selectively abolishes ONO 11113-evoked transient increment in [Ca22+].
    L 657925
  • HY-16635R
    Setipiprant (Standard)
    Antagonist
    Setipiprant (Standard) is the analytical standard of Setipiprant. This product is intended for research and analytical applications. Setipiprant (ACT-129968) is an orally active and selective CRTH2 antagonist. Setipiprant interacts with hCRTH2 receptor with an IC50 value of 6 nM. Setipiprant inhibits prostanoid receptors hDP1 and hEP2 with IC50 values of 1290 and 2600 nM, respectively. Setipiprant can be used for the research of asthma and rhinitis.
    Setipiprant (Standard)
  • HY-10418R
    AH 6809 (Standard)
    Antagonist
    AH 6809 (Standard) is the analytical standard of AH 6809. This product is intended for research and analytical applications. AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor.
    AH 6809 (Standard)
  • HY-119410
    Linotroban
    Antagonist
    Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent.
    Linotroban
  • HY-10794R
    MF498 (Standard)
    Antagonist
    MF498 (Standard) is the analytical standard of MF498 (HY-10794). This product is intended for research and analytical applications. MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis.
    MF498 (Standard)
  • HY-105218AR
    Ifetroban sodium (Standard)
    Antagonist
    Ifetroban sodium (Standard) is the analytical standard of Ifetroban sodium (HY-105218A). This product is intended for research and analytical applications. Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research.
    Ifetroban sodium (Standard)
  • HY-118895
    L-641953
    Antagonist
    L-641953 is an orally active, selective TXA/PG-END receptor (thromboxane-prostaglandin endoperoxide receptor) antagonist. L-641953 significantly inhibits arachidonic acid-induced bronchoconstriction. L-641953 may be used in cardiovascular disease research.
    L-641953
  • HY-105120
    Vapiprost
    Antagonist
    Vapiprost (GR 32191) is a thromboxane A2 receptor (TXA2 Receptor) antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10-8 M.
    Vapiprost
  • HY-16781R
    Grapiprant (Standard)
    Antagonist
    Grapiprant (Standard) is the analytical standard of Grapiprant. This product is intended for research and analytical applications. Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment .
    Grapiprant (Standard)
  • HY-U00423
    CRTH2-IN-1
    Antagonist
    CRTH2-IN-1 (Ramatroban analog) is a selective prostaglandin D2 receptor DP2 (CRTH2) antagonist with an IC50 of 6 nM in a human DP2 binding assay.
    CRTH2-IN-1
  • HY-100449A
    (S)-AL-8810
    Antagonist
    (S)-AL 8810 is an 11β-fluoro analog of PGF2α that acts as a potent and selective antagonist at the FP receptor. (S)-AL 8810 is the C-15 epimer of AL 8810, having the inverse, (S), or "natural" configuration at C-15 relative to AL 8810, which is 15-(R).
    (S)-AL-8810
  • HY-15950R
    AZD1981 (Standard)
    Antagonist
    AZD1981 (Standard) is the analytical standard of AZD1981. This product is intended for research and analytical applications. AZD1981 is the antagonist for GPR44 (also known also PTGDR2, DP2 or CRTh). AZD1981 blocks the binding of PGD2 to CRTH2. AZD1981 exhibits immunomodulatory effects and can be used in research of chronic spontaneous urticaria.
    AZD1981 (Standard)
  • HY-50901A
    ONO-AE3-208 sodium salt
    Antagonist
    ONO-AE3-208 (sodium salt) is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 (sodium salt) shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 (sodium salt) suppresses cell invasion, migration, and metastasis of prostate cancer.
    ONO-AE3-208 sodium salt
  • HY-160615
    TP receptor antagonist-1
    Antagonist
    TP receptor antagonist-1 (compound 7m) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease.
    TP receptor antagonist-1
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.